date,title,source
Oct-22-18,Ovid Therapeutics Receives Company Making a Difference Award from CDKL5 Deficiency Disorder Community,GlobeNewswire
Oct-22-18,"Ovid Therapeutics to Host Conference Call and Webcast on Thursday, October 25, at 10:30 a.m. EDT",GlobeNewswire
Oct-25-18,Ovid Therapeutics Presents Additional Data and Analyses from the Phase 2 STARS Clinical Trial with OV101 for the Treatment of Angelman Syndrome at the 65th AACAP Annual Meeting,GlobeNewswire
Nov-08-18,Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress,GlobeNewswire
Nov-16-18,"Granite Point Capitals Returns, AUM, and Holdings",Insider Monkey
Nov-20-18,Ovid Therapeutics Announces OV935/TAK-935 Presentations at the American Epilepsy Society 72nd Annual Meeting,GlobeNewswire
Dec-06-18,Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome,GlobeNewswire
Dec-17-18,Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies,GlobeNewswire
Dec-25-18,How Much Of Ovid Therapeutics Inc. (NASDAQ:OVID) Do Insiders Own?,Simply Wall St.
